**Core Concept**
The International Prognostic Index (IPI) is a clinical tool used to predict the outcome of patients with aggressive non-Hodgkin lymphoma. It is based on **five key prognostic factors** that help determine the likelihood of patient survival. These factors are related to the **tumor burden**, **patient performance status**, and **extranodal involvement**.

**Why the Correct Answer is Right**
The IPI includes factors such as **age**, **performance status**, **stage**, **lactate dehydrogenase (LDH) levels**, and **number of extranodal sites involved**. Each of these factors contributes to the overall prognosis by reflecting the **tumor burden**, **host response**, and **disease extent**. By considering these factors, clinicians can stratify patients into different risk groups, guiding treatment decisions and predicting outcomes.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because **age** is indeed a factor in the IPI, with patients older than 60 years having a worse prognosis.
**Option B:** This option is incorrect because **performance status**, as measured by the Eastern Cooperative Oncology Group (ECOG) scale, is also a component of the IPI.
**Option C:** This option is incorrect because **stage** of the disease, according to the Ann Arbor staging system, is included in the IPI.
**Option D:** Without the specific details of option D, we cannot directly address why it is incorrect, but based on the IPI components, any factor not listed (age, performance status, stage, LDH levels, number of extranodal sites) would be the correct answer.

**Clinical Pearl / High-Yield Fact**
The IPI is a crucial tool for **risk stratification** in lymphoma patients, helping to tailor treatment approaches to the individual's predicted outcome. Remembering the components of the IPI is essential for making informed decisions in clinical practice.

**Correct Answer:** D.